Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study

被引:2
|
作者
Commins, Isabella [1 ]
Clayton-Chubb, Daniel [1 ,2 ]
Melton, Sarah [3 ]
Majeed, Ammar [1 ,2 ]
Kemp, William [1 ,2 ]
Roberts, Stuart K. [1 ,2 ,4 ]
机构
[1] Alfred Hlth, Dept Gastroenterol, Melbourne, Australia
[2] Monash Univ, Cent Clin Sch, Dept Med, Melbourne, Australia
[3] Alfred Hlth, Dept Nutr & Dietet, Melbourne, Australia
[4] Alfred Ctr, Dept Gastroenterol, 99 Commercial Rd, Melbourne 3004, Australia
关键词
NAFLD; MAFLD; multidisciplinary; liver function tests; FibroScan; WEIGHT-LOSS; MANAGEMENT; DIAGNOSIS; IMPROVEMENT; RISK;
D O I
10.1111/imj.16055
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundNon-alcoholic fatty liver disease (NAFLD) is a major healthcare burden. Real-world outcomes in dedicated tertiary care settings in Australia remain unknown. AimTo evaluate the initial outcomes of patients referred to a dedicated multidisciplinary tertiary care NAFLD clinic. MethodsRetrospective review of all adult patients with NAFLD who attended a dedicated tertiary care NAFLD clinic between January 2018 and February 2020 and who had two clinic visits and FibroScans at least 12 months apart. Demographic and health-related clinical and laboratory data were extracted from electronic medical records. Key outcome measures were serum liver chemistries, liver stiffness measurement (LSM) and weight control at 12 months. ResultsA total of 137 patients with NAFLD were included. Median (interquartile range (IQR)) follow-up time was 392 days (343-497 days). One hundred and eleven patients (81%) achieved weight control (i.e. weight loss or stability). Markers of liver disease activity were significantly improved, including median (IQR) serum alanine aminotransferase (48 (33-76) vs 41 (26-60) U/L, P = 0.009) and aspartate aminotransferase (35 (26-54) vs 32 (25-53) U/L, P = 0.020). Median (IQR) LSM across the whole cohort was significantly improved (8.4 (5.3-11.8) vs 7.0 (4.9-10.1) kPa, P = 0.001). No significant reduction was observed in mean body weight or the frequency of metabolic risk factors. ConclusionsThis study highlights a new model of care for patients with NAFLD and demonstrates promising initial outcomes in relation to significant reductions in markers of liver disease severity. Although most patients achieved weight control, further refinements are needed to achieve significant weight reduction including more frequent and structured dietetic and/or pharmacotherapeutic interventions.
引用
收藏
页码:2065 / 2072
页数:8
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease
    Smith, Briohny W.
    Adams, Leon A.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (03) : 97 - 113
  • [42] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [43] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [44] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [45] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [46] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [47] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [48] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [49] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [50] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986